Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RACE trial in resectable gastroesophageal junction adenocarcinoma
2018-001728-20Phase 3Active
- Sponsor
- Heidelberg University
- Start
- Jan 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of fluorouracil, folinic acid, oxaliplatin and docetaxel in gastroesophageal junction adenocarcinoma (2 arms), sponsored by Heidelberg University. Primary endpoint: Progression-free survival. Started Jan 2020; status: active.
02
Drugs
fluorouracilfolinic acidoxaliplatindocetaxel
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2018-001728-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001728-20.